•Where is the biggest up and coming market for modalities?
•Where specific therapeutic areas amplify— or break—modality viability (oncology, rare disease, immunology, CNS)
•How modality choice shapes development risk, cost, and long-term platform value •Patient, payer & physician risk vs reward
Moderator: Miguel Gaspar, Senior Director, Oncology R&D, AstraZeneca
Panellists:
Peptides: Michelle Barnard, Director of Research, ValiRx
Oligos: Steve Hood, Senior Director, GSK
Biologics: Christopher Herring, Vice President of Biology & Safety, T-Therapeutics Immunotherapy: Jennifer Mataraza, Executive Director and Head, Translational Immuno-Oncology, Novartis
